Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

said both Wegovy and Zepbound have demonstrated clinically significant weight reduction in clinical trial programs. The statement also said, in part, that "robust data" supporting Wegovy's ...

Novo Nordisk told Reuters in a statement that a similar dose of Wegovy led to greater weight loss in a 2021 trial and one earlier this year than what was observed in the recent study. The company ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo ...